Business
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Thursday November 27, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Past
About this update from Inventiva Sa
[{"type":"image","alt":"INVENTIVA","displaySize":"","headline":null,"caption":"INVENTIVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IFR.Gz27ItPSlaHquTiPVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123","width":300,"height":142}},"lazy":false},{"type":"text","content":"Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting.","length":388,"tagName":"p"},{"type":"text","content":"The Combined Shareholders' Meeting was held on Thursday November 27, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Pierre Broqua.","length":191,"tagName":"p"},{"type":"text","content":"Mr. Pierre Broqua proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Eric Duranson, as secretary of the general meeting.","length":201,"tagName":"p"},{"type":"text","content":"All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 5th resolution, which had been the subject of a negative recommendation by the Board of Directors. The 5th resolution would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.","length":377,"tagName":"p"},{"type":"text","content":"Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for the Chief Executive Officer as described in the Combined Shareholders' Meeting notice brochure available on the Company's website under the heading “Shareholders' Meeting”.","length":346,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total number of shares composing the share ca...